Kuroki Mika, Short Abigail C, Coombs Lorinda A
Mika Kuroki.
Abigail C. Short.
Clin J Oncol Nurs. 2025 Mar 14;29(2):E37-E46. doi: 10.1188/25.CJON.E37-E46.
Chlorhexidine gluconate (CHG), an antimicrobial topical treatment, reduces central line-associated bloodstream infections (CLABSIs). However, many barriers exist to CHG use, limiting the benefits of this evidence-based intervention.
This review aimed to identify effective CHG interventions to reduce CLABSIs in patients with cancer, particularly those undergoing bone marrow transplantations.
PubMed® and CINAHL® databases were searched for articles published in English between 2014 and 2024 that focused on adults (aged 18 years or older) and evaluated CHG use, barriers to CHG use, and interventions to reduce CLABSI rates.
This review identified the following three themes: the efficacy of CHG on reducing hospital-acquired infections, barriers to CHG use, and multilevel educational programs that improve rates of CHG use.
葡萄糖酸氯己定(CHG)作为一种局部抗菌治疗药物,可降低中心静脉导管相关血流感染(CLABSI)的发生率。然而,CHG的使用存在诸多障碍,限制了这种循证干预措施的益处。
本综述旨在确定有效的CHG干预措施,以降低癌症患者,尤其是接受骨髓移植患者的CLABSI发生率。
检索PubMed®和CINAHL®数据库,查找2014年至2024年期间以英文发表的、聚焦于成年人(18岁及以上)且评估了CHG使用情况、CHG使用障碍以及降低CLABSI发生率干预措施的文章。
本综述确定了以下三个主题:CHG在降低医院获得性感染方面的疗效、CHG使用障碍以及提高CHG使用率的多层次教育项目。